Introducing Ten63 Therapeutics: Revolutionizing Drug Discovery with Computational Excellence. Durham-based startup Ten63 Therapeutics, founded by Marcel Frenkel, has secured an impressive $15.9 million in Series A funding from prominent investors SOSV, Hatteras Venture Partners, Draper Associates, and Sigma Group. Specializing in pharmaceutical manufacturing, Ten63 is at the forefront of pushing the boundaries of computational drug discovery. Their groundbreaking BEYOND platform allows them to design first and best-in-class therapeutics with enhanced durability against previously undruggable targets. With their proprietary drug discovery engine, BEYOND, Ten63 combines physics and AI in hyper-efficient search algorithms to pursue validated biological targets that exceed the capabilities of traditional therapeutic research. 

Leveraging their revolutionary technology, Ten63 explores an astounding 19,290,123 compounds per second, enabling them to identify solutions in unexplored chemical spaces. Their hyper-efficient search algorithms evaluate complex atomic interactions in 3D space with unprecedented speed and accuracy, uncovering novel solutions that no other method can achieve. Ten63's pioneering work in drug discovery is paving the way for a new generation of pharmaceutical advancements. With their focus on comprehensive search capabilities and true chemical diversity, Ten63 is poised to revolutionize the field of drug development.